Abstract 3117
Background
Cancer patients undergoing chemotherapy experienced many adverse effects. The purpose of this study was to assess the symptoms were experienced by cancer patients using the Edmonton Symptom Assessment scale.
Methods
The study was cross-sectional and was conducted in one-day clinic in large oncology hospital in capital of Greece. The sample consisted of 199 cancer patients undergoing chemotherapy in cycle 3. Date was collected using Edmonton Symptom Assessment Scale (ESAS) additionally with a questionnaire for demographic and clinical characteristics, Descriptive and conductive statistical methods were used.
Results
The vast majority of patients were women (n = 153, 76.9%) and had breast cancer (n = 153, 76,9%). Patients experienced mild severity symptoms as could be seen from the mean values of symptoms (physical symptoms: 14.85±10.25, emotional symptoms: 6.84±5.24, well-being 3.73±2.61). There is a statistically significant difference between type of cancer and shortness of breath (p = 0.015) between gender and nausea (p = 0.013) gender and shortness of breath (p = 0.013). In addition, there is statistically difference between drowsiness and how is chemotherapy given (p = 0.0017). The rest of the comparisons revealed that there is a statistical significant difference between pain and type of chemotherapy regimen (p = 0.014), nausea and type of chemotherapy regimen (p = 0.012), well-being and type of chemotherapy regimen (p = 0.003) as well as between total symptoms and type of chemotherapy regimen (p = 0.025).
Conclusions
Edmonton Symptom Assessment Scale was an important clinical instrument for assessing symptoms in clinical practice. There is a need for further research in order to use this tool in a daily clinical practice in one day chemotherapy clinic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract